Data On AVEO Pharmaceuticals’ Tivozanib And AV-203 To Be Presented At AACR Annual Meeting 2012

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and preclinical data on AV-203, AVEO’s ErbB3 inhibitory antibody, will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31-April 4, 2012 in Chicago.

“We look forward to sharing these data among our peers in the oncology research community at this year’s AACR meeting as we prepare to initiate clinical development with AV-203, our internally-discovered ErbB3 inhibitory antibody, in the first half of this year,” said Jeno Gyuris, Ph.D., senior vice president and chief scientific officer at AVEO. “ErbB3 is widely expressed in many human cancers and its over-expression is often associated with poor prognosis in patients. An increasing body of evidence implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 has demonstrated high affinity binding to ErbB3 and the ability to potently inhibit both ligand-dependent and ligand-independent ErbB3 signaling in vitro and in vivo.”

The schedule for AVEO’s poster presentations is as follows:

Date & Time:
          Sunday, April 1, 2012 from 1:00 to 5:00 p.m. (CDT)

Poster Title:
The effect of food on the pharmacokinetics of tivozanib

Abstract:

#752

Location:
McCormick Place West, Hall F, Poster Section 28, #6
 

Date & Time:
Monday, April 2, 2012 from 1:00 to 5:00 p.m. (CDT)

Poster Title:

 
AV-203, a humanized ErbB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ErbB3 signaling in vitro and in vivo

Abstract:
#2509

Location:
McCormick Place West, Hall F, Poster Section 19, #4
 

Date & Time:
Tuesday, April 3, 2012 from 8:00 a.m. to 12:00 p.m. (CDT)

Poster Title:
Pharmacokinetics and pharmacodynamics of AV-203, a humanized anti-ErbB3 antibody

Abstract:
#3787

Location:
McCormick Place West, Hall F, Poster Section 30, #22

Following the meeting, the AVEO posters will be available in the publications section of the AVEO website at investor.aveopharma.com.

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge

Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales